5 Key Takeaways

• 1

  Corneal tissue procedures are low in volume but critical for patient outcomes, often being sight-saving interventions.

• 2

  Medicare Advantage and private insurers frequently under-reimburse corneal tissue, straining ASCs and eye banks.

• 3

  ASCs must carefully review insurance contracts to ensure proper reimbursement for corneal transplant care.

• 4

  The lack of full reimbursement can lead to fewer corneal procedures at ASCs, pushing surgeries to hospitals.

• 5

  Reimbursement challenges can delay necessary corneal transplants, negatively impacting patient care and outcomes.